Photo from Nathan A. Pennell/X
Jan 13, 2024, 10:04
Nathan A. Pennell: Pralsetinib development outside the US and China also stopped
Nathan A. Pennell, Co-Director of the Cleveland Clinic Lung Cancer Program, shared a post by EGFR Resisters on X/Twitter:
“Oh man, pralsetinib (for RET+ tumors) development outside the US and China also stopped. Hope this gets resumed with new partners.”
Quoting EGFR Resisters’s post:
“Blueprint Medicines issued press release: “Discontinue further investment in the early clinical stage therapies BLU 945 and 451 for EGFR Non-Small Cell Lung Cancer and explore strategic options including potential outlicensing” Blu-945 and Blu-451 clinical trials will close.”
Source: Nathan A. Pennell/X and EGFR Resisters/X